Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in the size of the prostate gland. Symptoms may include frequent urination, trouble starting to urinate, a weak stream, inability to urinate, or loss of bladder control. Complications can include urinary tract infections, bladder stones, and chronic kidney problems. The cause is unclear.
Risk factors
- include family history, obesity, DMT2, not enough exercise, and ED.
- Medications like pseudoephedrine, anticholinergics, and calcium channel blockers may worsen symptoms.
- The underlying mechanism involves the prostate pressing on the urethra thereby making it difficult to pass urine out of the bladder.
Pathophysiology
- Hormonal influence:
- Dihydrotestosterone (DHT), formed from testosterone via 5-α-reductase, is the main androgen responsible for prostate growth.
- Accumulation of DHT in prostate tissue stimulates cell proliferation and decreases apoptosis.
- Estrogen may also contribute by upregulating androgen receptors in prostate tissue.
- Static (mechanical) component:
- Enlargement of the prostate physically compresses the urethra, increasing resistance to urinary flow.
- Dynamic (functional) component:
- Increased smooth muscle tone in the prostate and bladder neck mediated by α1-adrenergic receptors further narrows the urethral lumen.
Clinical Presentation
Lower Urinary Tract Symptoms (LUTS):
| Obstructive (voiding) symptoms | Irritative (storage) symptoms |
|---|---|
| Hesitancy, weak stream, straining to void, incomplete emptying, post-void dribbling | Frequency, urgency, nocturia, urge incontinence |
Complications
- Acute urinary retention
- Recurrent urinary tract infections
- Bladder stones
- Hydronephrosis and renal impairment (in severe untreated cases)
Diagnosis
- History & symptom assessment:
- AUA Symptom Index (IPSS) for severity scoring
- Rule out other causes (e.g., prostate cancer, infection)
- Physical examination:
- Digital rectal exam (DRE): smooth, enlarged, firm (not hard or nodular)
- Investigations:
- Urinalysis: exclude infection/hematuria
- Serum creatinine: assess renal function
- PSA (Prostate-Specific Antigen): optional; elevated in both BPH and prostate cancer
- Ultrasound (if indicated): bladder wall thickening, residual urine, prostate size
Pharmacologic Management (for Clinical Pharmacist)
| Drug Class | Example(s) | Mechanism of Action | Key Points / Monitoring |
|---|---|---|---|
| α₁-Adrenergic blockers | Tamsulosin, Alfuzosin, Doxazosin, Terazosin | Relax smooth muscle in prostate and bladder neck → ↓ dynamic obstruction | Rapid symptom relief (days–weeks); do not reduce prostate size. Monitor for orthostatic hypotension, dizziness, ejaculatory dysfunction. |
| 5-α-Reductase inhibitors | Finasteride, Dutasteride | Inhibit conversion of testosterone → DHT → ↓ prostate size and PSA by ~50% | Slow onset (months); indicated for enlarged prostate (>40 mL). Monitor PSA, sexual dysfunction (↓ libido, ED). |
| Combination therapy | Tamsulosin + Dutasteride (e.g., Jalyn®) | Targets both dynamic and static components | For patients with larger prostates and severe symptoms. |
| Phosphodiesterase-5 inhibitors | Tadalafil (Cialis®) | Enhances smooth muscle relaxation in prostate and bladder | Can be used in men with both BPH and erectile dysfunction. Avoid with nitrates. |
| Antimuscarinics / β₃-agonists | Oxybutynin, Solifenacin / Mirabegron | Treat overactive bladder symptoms | Use cautiously; may worsen urinary retention. |
Non-Pharmacologic Management
- Behavioral modification (reduce evening fluid intake, caffeine, alcohol)
- Bladder training
- Avoid medications that worsen symptoms (e.g., anticholinergics, sympathomimetics)
Surgical / Minimally Invasive Options
- Transurethral resection of the prostate (TURP) – gold standard
- Laser therapy, Urolift, or prostate ablation – for selected patients
Monitoring & Follow-Up (Pharmacist Focus)
| Parameter | Frequency | Notes |
|---|---|---|
| Symptom score (IPSS) | Every 3–6 months | Evaluate response to therapy |
| Blood pressure | For α-blockers | Monitor for orthostatic hypotension |
| PSA | Baseline and periodically | Expect ~50% reduction with 5-ARI |
| Sexual side effects | Ongoing | Common with 5-ARIs |
| Urinary retention / flow rate | Ongoing | Assess for progression or need for surgical referral |
Key Counseling Points
- α-blockers work quickly but do not shrink the prostate.
- 5-α-reductase inhibitors take months to work but reduce progression risk.
- Combination therapy improves symptoms and prevents long-term progression.
- Encourage adherence; discontinuation may worsen symptoms.